Codexis is a biotechnology company that engineers enzymes for pharmaceutical, fine chemicals, flavors & fragrances, agrochemicals and more. Codexis engineers custom enzymes and microorganisms, which are sometimes referred to as biocatalysts. The Company's Codexis' proprietary technology called CodeEvolver is directed evolution technology based on the concept that natural genetic mutation and selection can be accelerated in the research laboratory to obtain specific improvements in the function of single proteins and multiprotein pathways. CodeEvolver combines DNA shuffling and bioinformatics with systems biology to create new biocatalysts.


Type
Public
HQ
Redwood City, US
Founded
2002
Size (employees)
106 (est)
Codexis was founded in 2002 and is headquartered in Redwood City, US
Report incorrect company information

Key People/Management at Codexis

John Nicols

John Nicols

President & CEO
James Lalonde

James Lalonde

Senior Vice President, Research & Development

Codexis Office Locations

Codexis has an office in Redwood City
Redwood City, US (HQ)
200 Penobscot Dr
Show all (1)
Report incorrect company information

Codexis Financials and Metrics

Codexis Financials

Codexis's revenue was reported to be $50.02 m in FY, 2017
USD

Revenue (Q1, 2018)

14 m

Net income (Q1, 2018)

(4.7 m)

EBIT (Q1, 2018)

(4.7 m)

Market capitalization (22-Jun-2018)

843.9 m

Closing share price (22-Jun-2018)

15.9

Cash (31-Mar-2018)

24.3 m
Codexis's current market capitalization is $843.9 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

31.9 m35.3 m41.8 m48.8 m50 m

Revenue growth, %

11%18%17%

Cost of goods sold

9.8 m14.3 m

Gross profit

39.1 m35.7 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Revenue

3.9 m7.1 m6.6 m7.5 m6.8 m6 m17.4 m8 m16 m14.9 m8 m10.3 m14 m

Cost of goods sold

3 m3.8 m

Gross profit

5 m6.6 m

Gross profit Margin, %

62%63%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

22.1 m26.5 m23.3 m19.2 m31.2 m

Accounts Receivable

Inventories

1.5 m1.4 m992 k825 k1 m

Current Assets

35.8 m33 m32.8 m27.2 m45 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Cash

26.9 m23.2 m20.1 m21.5 m22.2 m16.6 m17 m22.2 m22.4 m14.9 m13.9 m28.8 m24.3 m

Inventories

2.1 m2 m2 m1.9 m992 k968 k678 k1 m1.2 m1.1 m1.1 m806 k1.2 m

Current Assets

36.6 m34.2 m26.9 m28.2 m27.6 m21.4 m32.3 m28.8 m27.9 m30.1 m21.7 m40.4 m36 m

PP&E

13.8 m7.4 m4.9 m4.4 m3.5 m3.2 m2.8 m2.8 m2.4 m2.3 m2.8 m3 m2.6 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(41.3 m)(19.1 m)(7.6 m)(8.6 m)(23 m)

Depreciation and Amortization

1 m

Inventories

(185 k)92 k403 k167 k(210 k)

Accounts Payable

308 k713 k(1.3 m)942 k(801 k)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Net Income

(9.3 m)(6.4 m)(8.5 m)(4.6 m)(5.6 m)(10.9 m)(5.5 m)(7 m)(4.7 m)(3.3 m)(7.5 m)(13.7 m)(4.7 m)

Depreciation and Amortization

238 k

Inventories

2 m992 k968 k678 k1 m1.2 m(84 k)(299 k)(177 k)

Accounts Payable

3.3 m2.5 m2 m(3 m)(3.5 m)(395 k)(492 k)(1 m)(882 k)(446 k)(975 k)
USDY, 2018

Financial Leverage

3 x
Show all financial metrics
Report incorrect company information

Codexis Online and Social Media Presence

Embed Graph
Report incorrect company information

Codexis News and Updates

Phenylketonuria (PKU) Market Key Players – American Gene Technologies International Inc, BioMarin Pharmaceutical Inc, Censa Pharmaceuticals Inc, Codexis Inc Analysis and Forecast to 2022

WiseGuyReports.com with their unique quality of simplifying the market research study, presents a deep diving study report “Phenylketonuria (PKU) - Pipeline Review, H1 2018” Posted via Industry Today. Follow us on Twitter @IndustryToday
Report incorrect company information